VVOS Vivos Therapeutics, Inc.
Nasdaq · SEC CIK 1716166 · EDGAR
- Bought, last 12 months
- $1.81M 1 purchases by 1 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 37 since 2021-08-10, latest 2026-09-18 20:20
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Skaff Michael C | 10% | $1.81M | — |
| Huntsman Ronald Kirk | CEO, Dir | — | — |
| Amman Bradford K. | Principal Accounting Off | — | — |
Transactions 10
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2026-09-18 17:04 | 2026-06-30 | VVOS | Huntsman Ronald Kirk | CEO, Dir | J - Other | $0.582 | +85.9K | 85.9K | New | +$50.0K |
| D | 2026-08-26 16:10 | 2026-07-31 | VVOS | Amman Bradford K. | Principal Accounting Off | A - Grant | $0.41 | +250.0K | 250.1K | +312,500% | +$102.5K |
| DMI | 2026-04-02 19:34 | 2026-03-31 | VVOS | Skaff Michael C | 10% | P - Purchase | $1.34 | +1.35M | 1.35M | New | +$1.81M |
| 2023-06-20 | 2023-06-20 | VVOS | Huntsman Ronald Kirk | CEO, Dir | P - Purchase | $0.53 | +14.0K | 86.5K | +19% | +$7,420 | |
| M | 2023-06-20 | 2023-06-15+ | VVOS | Huntsman Ronald Kirk | CEO, Dir | P - Purchase | $0.5366 | +15.0K | 57.5K | +35% | +$8,060 |
| 2023-06-15 | 2023-06-14 | VVOS | Huntsman Ronald Kirk | CEO, Dir | P - Purchase | $0.49 | +10.0K | 57.5K | +21% | +$4,900 | |
| D | 2022-12-28 | 2022-12-23 | VVOS | Huntsman Ronald Kirk | CEO, Dir, 10% | P - Purchase | $0.5 | +20.0K | 47.5K | +73% | +$10.0K |
| M | 2022-06-03 | 2022-05-31+ | VVOS | Huntsman Ronald Kirk | CEO, Dir, 10% | P - Purchase | $1.96 | +12.0K | 23.5K | +104% | +$23.6K |
| 2021-09-22 | 2021-09-21 | VVOS | Huntsman Ronald Kirk | CEO, Dir | P - Purchase | $4.31 | +5,000 | 15.5K | +48% | +$21.5K | |
| 2021-08-18 | 2021-08-17 | VVOS | Huntsman Ronald Kirk | CEO, Dir | P - Purchase | $3.00 | +5,000 | 10.5K | +91% | +$15.0K |
Purchase Sale Sale after option exercise All abbreviations